Acute Cardiac Dysfunction in Critical Illnes

Aetiology and Clinical Importance of Acute Cardiac Dysfunction in Critical Illness

The overall aim of the study is to establish the clinical importance of cardiac dysfunction, by estimating its incidence and impact on short- and long-term outcomes, in a mixed population of critically ill patients with multi-organ failure. Pathogenesis of cardiac dysfunction in critical illness and key molecules linked to this will be explored.

Study Overview

• Status: Recruiting
• Conditions: Myocardial Infarction; Right Ventricular Dysfunction; Multi Organ Failure; Left Ventricular Dysfunction; Tako Tsubo Cardiomyopathy; Cardiomyopathy, Stress
• Intervention / Treatment: Diagnostic test: Echocardiography; Diagnostic test: Cardiac magnetic resonance imaging; Diagnostic test: Coronary CT

Detailed Description

During critical illness, the heart is exposed to extreme external stressors, which may contribute to heart failure. There is a lack of knowledge of what happens to the heart over the course of critical illness. The few studies available suggest that LV dysfunction is common in critical illness, with a prevalence of 10-30%. Notably, LV regional hypokinesia is a frequent pattern of LV dysfunction among these patients and is associated with a higher risk of death.

LV regional hypokinesia during critical illness may have several possible aetiologies, including ischemic, inflammatory or other/mixed processes. Of these, acute coronary artery obstruction is probably most important. Patients with sepsis, for example, and acute ST elevation myocardial infarction have twice the risk of death. Type II myocardial infarction can also lead to LV dysfunction due to insufficient coronary artery flow e.g., from tachycardia, hypotension and hypoxia, resulting in myocardial ischemia. In the absence of CAD, LV regional hypokinesia could also result from myocardial inflammation secondary to systemic inflammatory response, direct toxic effects of cytokines or pathogenic infiltration. Another possible aetiology is Takotsubo syndrome, an acute cardiac condition characterised by reversible regional hypokinesia, usually in the apical portion of the LV. The current paradigm suggests that Takotsubo syndrome is triggered by the overstimulation of the myocardium by catecholamines and is closely correlated to events involving severe emotional or physical stress. Cardiac dysfunction in critical illness is likely a phenotype of Takotsubo syndrome since patients in the ICU undergo extreme stress and are exposed to both endogenously-released and exogenously-administered catecholamines.

In critical illness, accurate diagnosis of LV dysfunction is challenging due to the similar clinical presentation of potential aetiologies. However, diagnosing the underlying aetiology of LV dysfunction is essential to provide appropriate treatment and optimise outcomes. CAD can be diagnosed with coronary angiography and cardiac computed tomography (CCT). In the absence of CAD, cMRI is useful. cMRI can differentiate between myocardial ischemia, and inflammation, as well as between an acute or past event.

In this study, patients are examined with echocardiography to identify those with cardiac dysfunction. In a sub-set of patients with LV dysfunction, patients will be examined with coronary CT (if no angiography performed) and cardiac MRI. Blood samples are collected for storage in biobank.

• Study Type: Observational
• Enrollment (Estimated): 592

Contacts and Locations

• Study Contact: Name: Jonatan Oras, MD, PhD; Phone Number: +46313421000; Email: jonatan.oras@vgregion.se

Study Locations

• Sweden
  • Please Select
    • Västra Frölunda, Please Select, Sweden, 42668
      • Recruiting
      • Sahgrensak University Hospital
      • Contact: Jacob Holmqvist, MD; Email: jacob.holmqvist@vgregion.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with significant multi-organ dysfunction being admitted to a participaing ICU within 24 hours

Description

Inclusion Criteria:

1. Patients aged > 18 years
2. Admitted to a participating ICU within 24 hours

3. Significant organ dysfunction involving at least two organ systems. This is defined as fulfilling both of the following:

   • At least 4 points on the SOFA scale (Sequential Organ Failure Assessment scale)
   • Having at least 1 point on the SOFA scale from at least two organ systems
4. Given informed consent from patient or permission to participate from next of kin

Exclusion Criteria:

1. Echocardiographic examination not possible (e.g., pneumothorax, draping etc) or very low echocardiographic examination quality
2. Not being examined with echocardiography within 24 hours from inclusion
3. Retracted consent to participate

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Normal left ventricular systolic function; Patients with normal echocardiographic systolic function, defined as having left ventricular ejection fraction ≥ 50% and no regional hypokinesia	Diagnostic test: Echocardiography; All patients in the study will be examined with echocardiography
Left ventricular dysfunction; Patients with echocardiographic left ventricular systolic dysfunction, defines as having left ventricular ejection fraction < 50% or left ventricular regional hypokinesia in at least two adjacent segments	Diagnostic test: Echocardiography; All patients in the study will be examined with echocardiography; Diagnostic test: Cardiac magnetic resonance imaging; Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI; Other Names: cMRI; Diagnostic test: Coronary CT; Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT; Other Names: CCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
90-days mortality	Death	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Alive outside ICU	Days alive while not in the ICU	90 days
Alive without mechanical ventilation	Days alive and without mechanical ventilation	90 days
Alive without CRRT	Days alive without CRRT	90 days

Collaborators and Investigators

• Sponsor: Sahlgrenska University Hospital, Sweden

Study record dates

Study Major Dates

• Study Start (Actual): May 29, 2023
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): March 30, 2026

Study Registration Dates

• First Submitted: May 8, 2023
• First Submitted That Met QC Criteria: May 8, 2023
• First Posted (Actual): May 16, 2023

Study Record Updates

• Last Update Posted (Actual): October 6, 2023
• Last Update Submitted That Met QC Criteria: October 3, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Shock; Myocardial Infarction; Infarction; Cardiomyopathies; Ventricular Dysfunction; Ventricular Dysfunction, Right; Multiple Organ Failure; Takotsubo Cardiomyopathy; Ventricular Dysfunction, Left
• Other Study ID Numbers: SCCCS

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No